EMvision (ASX:EMV) share price slides 5% following FDA update

The FDA's feedback is critical in EMvision's growth narrative.

| More on:
A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The EMvision Medical Devices Ltd (ASX: EMV) share price has spent the morning in the red. It is currently changing hands for $2.91, down 5.21%.

EMvision's shares are on the move today after it announced an important update regarding a device application in the United States.

Here's what we know.

What did EMvision announce?

For context, EMvision is currently on the tools developing a portable medical imaging device that uses electromagnetic microwave imaging.

Its primary purpose is to diagnose the serious and complicated brain condition known as a stroke. However, it will diagnose other conditions as well.

EMvision advised it had received feedback from the US Food and Drug Administration (FDA) on its recent application for a Breakthrough Device Designation (BDD) in the US.

Under the Breakthrough Devices Program, applicants get priority review of their proposed therapy or intervention. This includes "interactive communication across the device development and validation path," per the release.

The release notes that preliminary evidence supports the use of its technology to "differentiate and localise" both types of stroke in patients.

However, the company reports that the FDA requires more clinical study data to support the case. It will need this before EMvision's device can get approval for the market.

As a result of the FDA feedback, EMvision advised it "has not been granted the BDD at this time."

It's not all over, though. The company still intends to go after the BDD once it has the clinical data on hand. EMvision will "generate [data] through further clinical development."

Importantly, the company emphasises that its pursuit of the "FDA De Novo regulatory marketing authorisation pathway" for its 1st Gen portable brain scanner product remains unaffected.

EMvision itself didn't appear to be fazed by the rejection. The medical tech company opting to take the feedback on board instead and get the ball rolling again.

Speaking on the announcement, EMvision CEO Dr Ron Weinberger said the company was "grateful for the quality feedback" provided by the FDA.

The decision has done little to deter the company's growth vision. Weinberger confirmed the marketing authorisation "remains unchanged, as does (its) preparation for expanded future clinical studies."

EMvision share price snapshot

The EMvision share price has had more than a choppy year so far, and has lagged the major benchmarks with a year-to-date loss of 5.81%.

Despite this, it's rallied 4% this past month, and is still 14% in the green over the past year.

Nonetheless, the EMvision share price has lagged the S&P/ASX 200 Index (ASX: XJO) gain of around 21% in the 12 months.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »